Metrics to compare | TELO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTELOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −1.9x | −0.2x | |
PEG Ratio | −0.08 | 0.01 | 0.00 | |
Price/Book | −2.9x | 0.4x | 2.6x | |
Price / LTM Sales | - | 2.6x | 2.8x | |
Upside (Analyst Target) | - | 35.6% | 61.2% | |
Fair Value Upside | Unlock | −9.6% | 9.7% | Unlock |
Telo Genomics Corp., a molecular diagnostics company, develops and commercializes diagnostic and prognostic products to personalize treatment plans for patients with specific conditions in Canada and Internationally. The company’s TeloView platform analyzes telomere structure and genomic instability to support disease prediction, risk assessment, and treatment selection. Its products include TeloView-SMM for smoldering multiple myeloma patients at risk of progression to multiple myeloma, TeloView NDMM for newly diagnosed multiple myeloma patients, TeloMRD-D for minimal residual disease detection, TeloViewNG-MRD for genomic instability profiling of residual disease cells, and TeloViewHL for Hodgkin’s lymphoma. The company also has a collaboration agreement with the Mayo Clinic for product development activities. Telo Genomics Corp. is headquartered in Toronto, Canada.